NASDAQ:WGS
GeneDx Holdings Corp.
GeneDx Holdings Corp.'s revenue grew 40.0% in fiscal 2025 to $427.5M while operating margin rose to −3.1%, its highest in 7 years. Free cash flow was $14.3M, 3.3% of revenue, and the diluted share count rose 6.5%.Summary generated from GeneDx Holdings Corp.'s SEC filings. Latest annual report filed Feb 23, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$427.5M
Revenue growth+40.0%
Revenue, 5-yr CAGR+19.0%
Gross margin69.7%
Operating margin−3.1%
Net margin−4.9%
ROIC−4.4%
Return on equity−7.6%
Debt / equity0.18
Free cash flow$14.3M
FCF margin3.3%
Share count change+6.5%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 212 | 235 | 203 | 305 | 428 |
| Operating income | −446 | −668 | −181 | −23 | −13 |
| Net income | −245 | −549 | −176 | −52 | −21 |
| Free cash flow | −200 | −326 | −185 | −34 | 14 |
Recent filings
- 4Insider transaction report
Sep 18, 2026 - 4Insider transaction report
Sep 18, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 3, 2026 - 8-KResults of operations and financial condition
Aug 3, 2026 - 8-KResults of a shareholder vote
Jun 23, 2026 - 8-KDirector or officer change
Jun 16, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 4, 2026 - 8-KResults of operations and financial condition
May 4, 2026